Welcome!
Home Tianjin Zhong Xin Pharmaceutical Group Corporation (TJZX)
M&A
Jinhushen Bio completes 67% acquisition with Tianjin Pharma, S shares offer price revised
The S shares offer price is revised from 89.3 US cents ($1.20) to 89.4 US cents due to a computation mistake.
March 27, 2021
M&A
Jinhushen Biological Medical Science and Technology to acquire 67% stake in Tianjin Zhong Xin’s controlling shareholder for undisclosed sum
As at Dec 20, TPH holds an interest of 42.8% of the total number of issued shares in the capital of Tianjin Zhong Xin.
December 21, 2020
Results
Tianjin Zhong Xin Pharma posts 10% rise in 2Q earnings to $30.8 mil
SINGAPORE (Aug 14): Tianjin Zhong Xin Pharmaceutical Group Corporation has recorded earnings of RMB 156.9 million ($30.8 million) or 0.20 RMB cents per share for the 2Q19 ended June, some 10% higher than earnings of RMB 142.2 million a year ago.
August 14, 2019
Broker's Calls
Here's why this Chinese pharmaceutical firm is hard to ignore
SINGAPORE (May 21): UOB Kay Hian is keeping its “buy” call on Tianjin Zhong Xin Pharmaceutical Group Corporation (TJZX) with an unchanged target price of US$1.72 – representing an upside of 43%.
May 21, 2018